Assuntos
Doença Celíaca/complicações , Arterite de Takayasu/complicações , Dor Abdominal/etiologia , Doença Celíaca/diagnóstico , Doença Celíaca/dietoterapia , Doença Celíaca/patologia , Dieta Livre de Glúten , Feminino , Gastroscopia , Humanos , Pessoa de Meia-Idade , Estômago/patologia , Arterite de Takayasu/diagnóstico por imagem , Arterite de Takayasu/terapiaAssuntos
Colite Ulcerativa , Síndrome de Hipersensibilidade a Medicamentos/diagnóstico , Infliximab/administração & dosagem , Pele/patologia , Síndrome de Sweet , Adulto , Azatioprina/efeitos adversos , Biópsia/métodos , Colite Ulcerativa/complicações , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/tratamento farmacológico , Fármacos Dermatológicos/administração & dosagem , Diagnóstico Diferencial , Glucocorticoides/administração & dosagem , Humanos , Masculino , Síndrome de Sweet/complicações , Síndrome de Sweet/diagnóstico , Síndrome de Sweet/tratamento farmacológico , Síndrome de Sweet/fisiopatologia , Resultado do TratamentoRESUMO
BACKGROUND: CT-P13 is a biosimilar of Remicade®, an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD. AIMS: To assess the effectiveness and safety of CT-P13 in IBD patients in real clinical practice. METHODS: This is a prospective observational study in patients with moderate to severe Crohn's disease or ulcerative colitis treated with CT-P13. The study was performed in one single center. Patients included were naive or switched to anti-TNF treatment from the reference infliximab (Remicade®) to CT-P13. Efficacy and safety were assessed in naive and switched patients who were in remission at the time of the switch at months 3 and 6 of therapy. RESULTS: 87.5 and 83.9% of switched CD patients who were in remission at the time of the switch continued in remission, and 66.7 and 50% of naive CD patients reached remission, at months 3 and 6. In UC switched cases, 92 and 91.3% of patients in remission at the time of the switch continued in remission, at 3 and 6 months. In naive UC patients, the remission rates were 44.4 and 66.7%, at months 3 and 6. Adverse events occurred in 7.5% of patients during 6 months of study. CONCLUSIONS: CT-P13 was efficacious and well tolerated in patients with CD or UC.